Arcutis Biotherapeutics, Inc. (ARQT)
27.53
-0.85
(-3.00%)
USD |
NASDAQ |
Nov 12, 16:00
28.18
+0.65
(+2.36%)
After-Hours: 07:17
Arcutis Biotherapeutics Shareholders Equity (Quarterly) : 243.97M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 243.97M |
| June 30, 2026 | 220.58M |
| March 31, 2026 | 189.65M |
| December 31, 2025 | 189.48M |
| September 30, 2025 | 158.07M |
| June 30, 2025 | 138.97M |
| March 31, 2025 | 142.66M |
| December 31, 2024 | 157.54M |
| September 30, 2024 | 156.64M |
| June 30, 2024 | 186.43M |
| March 31, 2024 | 224.94M |
| December 31, 2023 | 88.67M |
| September 30, 2023 | 46.72M |
| June 30, 2023 | 80.51M |
| March 31, 2023 | 139.73M |
| December 31, 2022 | 209.58M |
| Date | Value |
|---|---|
| September 30, 2022 | 270.77M |
| June 30, 2022 | 195.38M |
| March 31, 2022 | 253.77M |
| December 31, 2021 | 297.68M |
| September 30, 2021 | 363.00M |
| June 30, 2021 | 414.49M |
| March 31, 2021 | 450.99M |
| December 31, 2020 | 270.62M |
| September 30, 2020 | 173.07M |
| June 30, 2020 | 208.92M |
| March 31, 2020 | 241.88M |
| December 31, 2019 | 101.46M |
| September 30, 2019 | 19.30M |
| June 30, 2019 | 33.59M |
| March 31, 2019 | |
| December 31, 2018 | 48.26M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.387B |
| ADMA Biologics, Inc. | 438.51M |
| Alnylam Pharmaceuticals, Inc. | 3.604B |
| Anika Therapeutics, Inc. | 137.58M |
| Savara, Inc. | 107.85M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 524.43M |
| Total Liabilities (Quarterly) | 280.46M |
| Debt to Equity Ratio | 0.5075 |
| Current Ratio | 2.922 |
| Net Debt Paydown Yield | -0.08% |